Is Kobo Biotech Ltd (531541) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kobo Biotech Ltd is a average quality company .

Is Kobo Biotech Ltd (531541) undervalued or overvalued?

The key valuation ratios of Kobo Biotech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Kobo Biotech Ltd (531541) share price return in the past 10 years?

Kobo Biotech Ltd share price has declined -19.2% annually (CAGR) over the past ten years.

Is Kobo Biotech Ltd (531541) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kobo Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Kobo Biotech Ltd (531541)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kobo Biotech Ltd (531541) on 17-Apr-2026 16:59:59 at 16:59 is 2.74.

What is the P/E ratio of Kobo Biotech?

The latest standalone P/E ratio of Kobo Biotech as of 17-Apr-2026 is 0.00.

What is the P/B ratio of Kobo Biotech Ltd (531541)?

The latest standalone P/B ratio of Kobo Biotech Ltd (531541) as of 17-Apr-2026 is 0.00.

What is the 52-week high and low of Kobo Biotech Ltd (531541)?

The 52-week high of Kobo Biotech Ltd (531541) is Rs. 3.58 and the 52-week low is Rs. 1.99.

Kobo Biotech Ltd (531541) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kobo Biotech Ltd (531541)
Brand: Kobo Biotech

Kobo Biotech Ltd (531541) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kobo Biotech Ltd (531541)

BSE: 531541 NSE:

Key Metrics

Market Cap

₹7 Cr.

P/E Ratio

0.00

Price to Book (P/B)

0.00

Price to Sales (P/S)

0.00

EV/EBITDA

-151.96

Return on Capital Employed (ROCE)

-36.84%

Current Price

₹2.7

Return on Equity (ROE)

0.00%

Return on Assets (ROA)

-7.19%

Operating Profit Margin

Net Profit Margin

-INF%

Gross Profit Margin

Book Value per Share

₹0

Sales Growth (YoY)

NA%

Sales Growth (3 Years)

NA%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

N/A%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹2 / 4

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

44.95%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Kobo Biotech Ltd?

Kobo Biotech Ltd revenue growth is 0% for FY-2023 , which is in line with its 5 year CAGR of 0% , indicating stable growth.

Q.1 Promoter shareholding and pledge status of Kobo Biotech Ltd?

Promoters hold 44.95% of the Kobo Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Kobo Biotech Ltd vs industry peers?

Kobo Biotech Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating stable growth and maintaining its market share.

Q.1 Which industry/sub-sector does Kobo Biotech Ltd belong to?

Kobo Biotech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Kobo Biotech Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -21% based on the current price.

DeciZen - make an informed investing decision on Kobo Biotech

Based on:

Data

M-Cap below 100cr DeciZen not available

Kobo Biotech stock performance

Key Ratios

Is Kobo Biotech Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	-7.1%	-8.7%	-1.3%	-2.8%	-5.1%	-5.7%	-3.9%	-5.3%	-17.6%	-36.8%	-
Value Creation Index ⓘ	-1.5	-1.6	-1.1	NA	NA	NA	NA	NA	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	56.9	29.1	32.5	0	0	0	0	0	0	0	0
Sales YoY Gr.	-	-48.9%	12%	-100%	NA	NA	NA	NA	NA	NA	-
Adj EPS ⓘ	-15.3	-14.4	-7.2	-8	-10.1	-10	-9.4	-7.9	-0.2	-2.2	-2.1
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	19.8	6.1	0.2	-7.8	-17.8	-28.1	-36.9	-45	-51.4	-53.7	0
Adj Net Profit ⓘ	-34.3	-32.4	-17.1	-19.2	-24	-23.8	-22.4	-18.8	-0.4	-5.2	-5
Cash Flow from Ops. ⓘ	11	19.3	5.6	32.3	31.5	21	14.5	2.5	93.8	0.9	-
Debt/CF from Ops. ⓘ	12.4	7.4	27.2	6.4	7.1	11.3	17.3	103.8	1.5	159.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-100%	NA	NA	NA
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-211.7%	NA	NA	NA
Share Price	-19.2%	-15.5%	0.9%	-7.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	-56.4	-111.1	-170.2	315.3	78.5	43.5	28.9	19.3	0.4	4.1	7.9
Op. Profit Mgn % ⓘ	-12.2	-34.2	11.9	0	0	0	0	0	0	0	NAN
Net Profit Mgn % ⓘ	-60.3	-111.4	-52.6	0	0	0	0	0	0	0	-INF
Debt to Equity ⓘ	3.1	10.4	384.1	-11.2	-5.2	-3.5	-2.9	-2.4	-1.2	-1.1	-
Working Cap Days ⓘ	988	1,875	1,675	0	0	0	0	0	0	0	0
Cash Conv. Cycle ⓘ	641	1,235	711	0	0	0	0	0	0	0	0

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	-2.1	-14.6
TTM Sales (₹ Cr.)	0	103
BVPS (₹) ⓘ	0	0
Reserves (₹ Cr.) ⓘ	-158	31
P/BV ⓘ	0.00	0.00
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	1.99 / 3.58
All Time Low / High (₹)	1.19 / 82.55
Market Cap (₹ Cr.)	6.5
Equity (₹ Cr.)	23.8
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Kobo Biotech - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	56.89	29.06	32.54	0	0	0	0	0	0	0
Operating Expenses ⓘ +	63.84	38.98	28.66	4.04	3.08	2.99	2.61	2.79	143.87	1.50
Manufacturing Costs	5.28	1.23	3.41	0.34	0.24	0.31	0.42	0.28	0.10	0.12
Material Costs	47.42	28.49	19.50	0	0	0	0	0	0	0
Employee Cost	9.03	6.17	4.27	3.11	2.42	2.08	1.80	1.39	0.72	0.23
Other Costs ⓘ	2.11	3.09	1.49	0.59	0.42	0.60	0.39	1.11	143.05	1.15
Operating Profit ⓘ	-6.95	-9.93	3.88	-4.04	-3.08	-2.99	-2.61	-2.79	-143.87	-1.50
Operating Profit Margin (%)	-12.2%	-34.2%	11.9%	-	-	-	-	-	-	-
Other Income ⓘ +	2.68	0.53	1.35	6	0.10	1.31	1.95	0.04	133.38	0.02
Exceptional Items ⓘ	0	2.54	0	0	0	-2.18	0	0	0	0
Interest ⓘ	18.14	15.62	14.37	14.41	14.50	14.44	14.47	10.84	0.13	0
Depreciation ⓘ	9.62	7.78	7.31	6.78	6.44	6.15	5.88	5.64	4.61	4.07
Profit Before Tax ⓘ	-32.03	-30.26	-16.46	-19.24	-23.92	-24.46	-21.01	-19.23	-15.23	-5.55
Tax ⓘ	0.54	0	0	0	0	0	0	0	0	0
Profit After Tax	-32.57	-30.26	-16.46	-19.24	-23.92	-24.46	-21.01	-19.23	-15.23	-5.55
PAT Margin (%)	-57.3%	-104.0%	-50.6%	-	-	-	-	-	-	-
Adjusted EPS (₹)	-14.5	-13.5	-6.9	-8.1	-10.0	-10.3	-8.8	-8.1	-6.4	-2.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund +	44.57	13.67	0.40	-18.58	-42.51	-66.96	-87.97	-107.20	-122.43	-127.98
Share Capital ⓘ	22.50	22.50	23.73	23.83	23.83	23.83	23.83	23.83	23.83	23.83
Reserves ⓘ	22.07	-8.83	-23.33	-42.41	-66.33	-90.79	-111.80	-131.03	-146.25	-151.81
Debt +	129.15	127.47	134.91	179.17	176.56	184.46	198.86	208.26	93.29	92.42
Long Term Debt	44.27	39.39	39.28	58.41	41.43	34.93	34.93	33.53	33.53	32.66
Short Term Debt	84.88	88.07	95.63	120.76	135.13	149.53	163.93	174.73	59.76	59.76
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	52.58	51.48	58.34	50.10	51.51	54.46	57.08	60.45	52.17	54.74
Others Liabilities ⓘ	52.70	59.22	66.82	41.53	60.38	67.49	68.36	69.08	56.15	56.16
Total Liabilities ⓘ	279	251.83	260.47	252.22	245.94	239.45	236.33	230.59	79.19	75.33
Fixed Assets
Net Fixed Assets ⓘ +	103.52	95.10	87.79	81.01	74.56	68.42	62.54	56.91	41.66	37.59
Gross Block	192.41	192.41	192.41	192.41	192.41	192.42	192.42	192.42	103.68	103.68
Accumulated Depreciation	88.89	97.31	104.62	111.41	117.85	124	129.88	135.51	62.02	66.09
CWIP ⓘ	2.25	2.25	2.25	2.25	2.25	2.25	2.25	2.25	0	0
Investments ⓘ	12.19	12.19	12.19	12.19	12.19	12.19	12.19	12.19	0	0
Inventories	76.01	69.97	55.46	55.46	55.46	53.28	53.28	53.28	18.04	18.04
Trade Receivables	65.31	56.16	89.73	88.74	88.83	90.61	93.29	92.47	11.80	11.95
Cash Equivalents	1.42	0.24	0.59	0.13	0.13	0.13	0.13	1.56	0.13	0.13
Others Assets ⓘ	18.30	15.92	12.45	12.44	12.51	12.57	12.65	11.93	7.56	7.62
Total Assets ⓘ	279	251.83	260.47	252.22	245.94	239.45	236.33	230.59	79.19	75.33

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ +	11.02	19.32	5.62	32.30	31.47	20.95	14.48	2.51	93.76	0.87
PBT ⓘ	-32.03	-30.26	-16.46	-19.24	-23.92	-24.46	-21.01	-19.23	-15.23	-5.55
Adjustment ⓘ	27.76	23.40	21.69	21.19	20.94	20.59	20.35	16.48	4.74	4.07
Changes in Working Capital ⓘ	15.84	26.18	0.39	30.35	34.45	24.82	15.13	5.26	104.24	2.36
Tax Paid ⓘ	-0.54	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-4.71	0	0	0	0	-0	-0	0	25.09	0
Capex	-4.71	0	0	0	0	-0	-0	0	12.89	0
Net Investments	0	0	0	0	0	0	0	0	12.19	0
Others ⓘ	0	0	0	0	0	0	0	0	0.01	0
Cash Flow From Financing Activity ⓘ +	-7.01	-20.50	-5.27	-32.76	-31.47	-20.95	-14.47	-1.08	-120.28	-0.87
Net Proceeds from Shares ⓘ	0	0	3.19	0.26	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	11.13	-4.88	-0.11	-12.59	-16.97	-6.50	0	-1.40	0	-0.87
Interest Paid ⓘ	-18.14	-15.62	-14.37	-14.41	-14.50	-14.44	-14.47	-10.84	-0.13	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	6.03	-6.03	0	0	0	11.16	-120.15	0
Net Cash Flow ⓘ	-0.69	-1.18	0.35	-0.46	0	-0	-0	1.43	-1.43	0

Finance Ratio

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	-53.52	-103.9	-233.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROCE (%)	-7.12	-8.67	-1.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover Ratio	0.21	0.11	0.13	0	0	0	0	0	0	0
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	438	755	815	0	0	0	0	0	0	0
Inventory Days	428	907	701	0	0	0	0	0	0	0
Payable Days	324	666	1,028	0	0	0	0	0	0	0

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kobo Biotech Ltd FAQs

The current trading price of Kobo Biotech on 17-Apr-2026 16:59 is ₹2.74.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Kobo Biotech stood at ₹6.53 Cr

The latest P/E ratio of Kobo Biotech as of 16-Apr-2026 is 0.00.

The latest P/B ratio of Kobo Biotech as of 16-Apr-2026 is 0.00.

The 52-week high of Kobo Biotech is ₹3.58 and the 52-week low is ₹1.99.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kobo Biotech is ₹0.00 ( Cr.) .

About Kobo Biotech Ltd

AVON Organics Limited (AOL) was started by P R Agarwal, Rajesh Agarwal along with late G S Sidhu .It is located at Madhupala Towers Greenlands, Hyderabad 500 016, India. The company's transition from a machinery manufacturer to a full-fledged chemical manufacturer saw the company foraying into the highly technology-intensive area of Diketene and its derivatives.

In the year 1996 the company established and successfully commissioned its first grass root Diketene plant .It has doubled its production capacity by commissioning an additional 1000 TPA unit as part of its second phase in 1998. It is an ISO 9000 certification by the Lloyds Register Quality Assurance (LRQA).

Business profile:

A keen insight and a well-planned development process saw AOL discover the opportunity in the production of Diketene - the basic unit for hundreds of derivatives in pesticides, chemicals, pharmaceuticals and dyestuffs. A highly classified technology, it has been sourced from Shanghai Peng Pu Chemical Works, China, and Xytel Technology Partnership, USA, and now rests in the hands of a few chosen manufacturers across the globe.

The company, with its immense infrastructure framework has introduced modifications to the Chinese technology and has a current production of 3000 tonnes per annum against an installed capacity of 2000 tonnes per annum. A sprawling facility of 21 acres, the plant is situated 60 kilometers from Hyderabad. The locale is ideal due to its easy connectivity made possible by the well-traversed National Highway # 9 that links Hyderabad with Mumbai.

Products :

Diketene:
Pharmaceutical intermediates
Agrochemical intermediates
Pigment intermediates

Pharmaceutical (Including Ephedrines) :

Active Pharmaceutical ingredients
Pharma intermediates
Formulation intermediates

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Kobo Biotech Ltd (531541) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Kobo Biotech Share Price